Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
4(100.0%)
4Total
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01654120Phase 4Completed

Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

Role: lead

NCT04409587Phase 4Completed

Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump

Role: lead

NCT04414579Phase 4Unknown

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

Role: lead

NCT00606034Phase 4Completed

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

Role: lead

All 4 trials loaded